Literature DB >> 11207052

Oestrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer.

F Takama1, T Kanuma, D Wang, I Kagami, H Mizunuma.   

Abstract

We assessed the relative expression of oestrogen receptor (ER)alpha and oestrogen receptor (ER)beta mRNAs in 36 human endometrial cancers using a multiplex polymerase chain reaction (PCR). To determine whether or not the expression of ER subtypes in endometrial cancers is associated with clinicopathological parameters, we examined correlations between ER subtypes and age, tumour grade and depth of myometrial invasion. Using multiple regression analysis, myometrial invasion showed a significant correlation with ER-beta: ER-alpha ratio (r = 0.54, P = 0.0007). The ER-beta:ER-alpha ratio was high in advanced invasive carcinoma. Western blotting analysis showed that ER-beta proteins were highly expressed in comparison with ER-alpha proteins in endometrial cancer with severe myometrial invasion. Our results suggest that ER-beta is important in the progression of myometrial invasion. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11207052      PMCID： PMC2363767          DOI： 10.1054/bjoc.2000.1589

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  20 in total

1.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.

Authors:  G G Kuiper; B Carlsson; K Grandien; E Enmark; J Häggblad; S Nilsson; J A Gustafsson
Journal:  Endocrinology       Date:  1997-03       Impact factor: 4.736

3.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

4.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

5.  Expression of estrogen receptor-beta in human breast tumors.

Authors:  H Dotzlaw; E Leygue; P H Watson; L C Murphy
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

6.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

Authors:  G B Tremblay; A Tremblay; N G Copeland; D J Gilbert; N A Jenkins; F Labrie; V Giguère
Journal:  Mol Endocrinol       Date:  1997-03

7.  Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen.

Authors:  S M Hyder; G M Stancel; C Chiappetta; L Murthy; H L Boettger-Tong; S Makela
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

8.  Steroid hormone receptor content and lymph node status in endometrial cancer.

Authors:  P C Morris; J R Anderson; B Anderson; R E Buller
Journal:  Gynecol Oncol       Date:  1995-03       Impact factor: 5.482

9.  Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer.

Authors:  L G Friberg; H Norén
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

10.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  C P Morrow; B N Bundy; R J Kurman; W T Creasman; P Heller; H D Homesley; J E Graham
Journal:  Gynecol Oncol       Date:  1991-01       Impact factor: 5.482
View more
  6 in total

1.  Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Yasushi Kiyono; Tetsuji Kurokawa; Takashi Kudo; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

2.  Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma.

Authors:  Jieyu Wang; Nan Jia; Qing Li; Chao Wang; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

3.  The cervical malignant cells display a down regulation of ER-α but retain the ER-β expression.

Authors:  Ricardo López-Romero; Efraín Garrido-Guerrero; Angélica Rangel-López; Leticia Manuel-Apolinar; Patricia Piña-Sánchez; Minerva Lazos-Ochoa; Alejandra Mantilla-Morales; Cindy Bandala; Mauricio Salcedo
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

4.  Involvements of Estrogen Receptor, Proliferating Cell Nuclear Antigen and p53 in Endometrial Adenocarcinoma Development in Donryu Rats.

Authors:  Midori Yoshida; Shin-Ichi Katsuda; Akihiko Maekawa
Journal:  J Toxicol Pathol       Date:  2012-12-20       Impact factor: 1.628

5.  Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.

Authors:  A M Kamal; J N Bulmer; S B DeCruze; H F Stringfellow; P Martin-Hirsch; D K Hapangama
Journal:  Br J Cancer       Date:  2016-03-01       Impact factor: 7.640

6.  Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.

Authors:  Takeshi Obata; Mitsuhiro Nakamura; Yasunari Mizumoto; Takashi Iizuka; Masanori Ono; Jumpei Terakawa; Takiko Daikoku; Hiroshi Fujiwara
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.